AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Create a link to this page

Copy and paste this link tag into your Web page or blog:

<a href="http://www.accessmylibrary.com/coms2/summary_0286-25444184_ITM" title="Facts and information about Janssen, L.P. Selects INVEGA(TM) (paliperidone) Extended Release tablets as Brand Name for Its Investigational Atypical Antipsychotic.">Janssen, L.P. Selects INVEGA(TM) (paliperidone) Extended Release tablets as Brand Name for Its Investigational Atypical Antipsychotic.</a>

Close Set up an RSS feed that alerts you when new articles from PR Newswire are available.

Frequently asked questions about RSS feeds

Janssen, L.P. Selects INVEGA(TM) (paliperidone) Extended Release tablets as Brand Name for Its Investigational Atypical Antipsychotic.

PR Newswire

| November 10, 2006 | COPYRIGHT 2009 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

TITUSVILLE, N.J., Nov. 10 /PRNewswire/ -- Janssen, L.P., a wholly owned subsidiary of Johnson & Johnson, announced that it has selected INVEGA(TM) as the brand name for paliperidone extended release tablets, the company's investigational oral atypical antipsychotic. The company is seeking approval from the U.S. Food and Drug Administration (FDA) to market INVEGA(TM) for the treatment of schizophrenia.

The FDA recently informed the company that it has assigned a class 1 (i.e., two month) review for INVEGA(TM). The new user fee goal date for an FDA action on the new drug application (NDA) is now December 20, 2006.

Johnson & Johnson Pharmaceutical Research &…

View articles courtesy of your local library

Related articles from newspapers, magazines, journals, and more


Lexicon Genetics Announces OmniBank(R) Internet Universal(TM) Agreement With...: Press release article from: PR Newswire January 27, 2000 700+ words
...The R.W. Johnson Pharmaceutical Research Institute (PRI...Internet Universal(TM) program. PRI will...Validation (S-T-V(TM)) program to determine...proprietary Human Gene Trap(TM) database, OmniBank...The R.W. Johnson Pharmaceutical Research Institute, Lexicon...


Trega Biosciences Announces Janssen Research Foundation and The R.W. Johnson...: Press release article from: PR Newswire October 12, 2000 700+ words
...JRF) and The R.W. Johnson Pharmaceutical Research Institute (PRI), members...modules of Trega's iDEA(TM) predictive models -- absorption and metabolism. The iDEA(TM) models are designed to simulate...worldwide license to the iDEA(TM) absorption and metabolism...


ArQule, Inc. and The R. W. Johnson Pharmaceutical Research Institute Add...: Press release article from: PR Newswire September 19, 2000 700+ words
...their 1998 collaboration agreement with The R.W. Johnson Pharmaceutical Research Institute ("PRI"), a Johnson & Johnson Company...agreement includes the addition of ArQule's Compass Array(TM) libraries, which can be screened by PRI and other Johnson...


Affymetrix Signs GeneChip(R) EasyAccess(TM) Silver Agreement With Janssen...: Press release article from: PR Newswire July 10, 2000 700+ words
...R.W. Johnson Pharmaceutical Research Institute Obtain...R.W. Johnson Pharmaceutical Research Institute (PRI...an EasyAccess(TM) Silver agreement...for use in their pharmaceutical research and development...


Acusphere Announces Publication in ''Pharmaceutical Research'' on Hydrophobic...: Press release article from: Business Wire April 26, 2005 700+ words
...Hydrophobic Drug Delivery Systems (HDDS(TM)), has been published in "Pharmaceutical Research", Volume 22, Number 3, March 2005...administration including oral. ""Pharmaceutical Research" is one of the most respected pharmaceutical...


ALLIANCE PHARMACEUTICAL CORP. ANNOUNCES LICENSING AGREEMENT WITH ORTHO BIOTECH...: Press release article from: PR Newswire August 16, 1994 700+ words
...W. Johnson Pharmaceutical Research Institute for OXYGENT(TM), Alliance...W. Johnson Pharmaceutical Research Institute...of OXYGENT(TM)," said Duane...W. Johnson Pharmaceutical Research Institute...


Abbott Laboratories Reviews Pharmaceutical Research and Development...: Press release article from: PR Newswire May 29, 2003 700+ words
...opportunities with approximately 14 projected regulatory filings for additional indications for key existing drugs, such as HUMIRA(TM) (adalimumab), and new compounds through 2006. Abbott's global pharmaceutical strategy has focused on optimizing the organizational...


Isis Pharmaceuticals' GeneTrove Division and the R.W. Johnson Pharmaceutical...: Press release article from: PR Newswire August 3, 2000 700+ words
...today that its GeneTrove (TM) division has initiated an...collaboration with The R.W. Johnson Pharmaceutical Research Institute (PRI), a member...first product, Vitravene(TM), (fomivirsen), to treat...in RNA: Ibis Therapeutics (TM), a division that is focused...


GeneGo Expands License With Johnson & Johnson Pharmaceutical Research &...: Press release article from: PR Newswire February 20, 2006 700+ words
...that Johnson & Johnson Pharmaceutical Research & Development, (J...extended their MetaCore(TM) license to now include MetaBase(TM), a database J&JPRD...second product, MetaDrug(TM) is designed for prediction...


NaviCyte, a Trega Biosciences Company, Announces Signing the R.W. Johnson...: Press release article from: PR Newswire March 24, 1999 700+ words
...W. Johnson Pharmaceutical Research Institute...W. Johnson Pharmaceutical Research Institute...s IDEA(TM) Consortium...Informatics(TM) software...W. Johnson Pharmaceutical Research Institute...

For more facts and information, see all results

Source: HighBeam Research, Janssen, L.P. Selects INVEGA(TM) (paliperidone) Extended Release...

The AccessMyLibrary advertising network includes: